Merck announced on March 31, 2025, detailed positive results from the Phase 3 ZENITH trial for WINREVAIR (sotatercept-csrk). The study showed that WINREVAIR reduced the risk of a composite of all-cause death, lung transplantation, and hospitalization for pulmonary arterial hypertension (PAH) by 76% compared to placebo.
This significant reduction was observed in adults with PAH, on top of background PAH therapy. The ZENITH trial met its primary endpoint of time to first morbidity or mortality event, reinforcing the drug's strong efficacy profile.
These highly compelling data further solidify WINREVAIR's position as a transformative treatment for PAH, a rare and life-threatening condition. The results are expected to support broader adoption and expand the drug's commercial potential, making it a key growth driver for Merck.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.